![]() |
||||||
|
Dataset: GSE161801_IMiD |
Dataset summary for GSE161801_IMiD |
Datast information | Dataset | GSE161801_IMiD |
PMID | 34845188 | |
Raw data ID/link | EGAD00001006903 | |
Organism | Homo sapiens | |
Source | patients | |
Tissue | Bone marrow aspirate | |
Cancer type level1 | Multiple myeloma | |
Cancer type level2 | Refractory multiple myeloma (MM) | |
Regimen | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | |
Drug type | Targeted therapy | |
Sample size | pre (resistant 6, sensitive 2); post (resistant 6, sensitive 3) | |
Cell number | 85449 | |
Extract protocol | 10x genomics | |
Data processing | CellRanger 3.0.1 | |
Public date | Public on Aug 18, 2021 | |
Description | This dataset has 9 patients, 8 of whom have both pre- and post-treatment samples. |
Top |
Drug summary for GSE161801_IMiD |
Drug name | DrugBank ID | Drug type | Targets name | Targets uniprot ID |
"Pomalidomide" | DB08910 | small molecule | CRBN; TNF; PTGS2 | Q96SW2; P01375; P35354 |
"Lenalidomide" | DB00480 | small molecule | CRBN; TNFSF11; CDH5; PTGS2 | Q96SW2; O14788; P33151; P35354 |
"Dexamethasone" | DB01234 | small molecule | NR3C1; NR0B1; ANXA1; NOS2; NR1I2 | P04150; P51843; P04083; P35228; O75469 |
Top |
Umap of single cell types and conditions (resistant and sensitive) |
![]() |
Umap of cell types![]() | Umap of conditions![]() |
Top |
Comparison of cell composition between the resistant and sensitive groups |
![]() * represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.) |
![]() * represents significant difference. (If the image exists, the user can click on it to enlarge it in a new window.) |
![]() |
Top |
Comparison of ITH and EMT scores of malignant cells between the resistant and sensitive groups |
![]() |
Comparison of ITH scores![]() | Comparison of EMT scores![]() |
Top |
Difference of cell-cell interactions between the resistant and sensitive groups |
![]() |
resistant vs. sensitive ![]() |
Dot plot of significant ligand-receptor pairs in the resistant group | Dot plot of significant ligand-receptor pairs in the sensitive group |
![]() | ![]() |
![]() |
resistant vs. sensitive ![]() |
Dot plot of significant ligand-receptor pairs in the resistant group | Dot plot of significant ligand-receptor pairs in the sensitive group |
![]() | ![]() |
![]() |
Top |
Differentially expressed genes (DEGs) between the resistant and sensitive groups for each cell type |
![]() |
Gene symbol | Gene id | avg_log2FC | p_val | p_val_adj | pct.1 | pct.2 | Cell type | Timepoint |
JUND | ENSG00000130522 | 0.878288 | 0.00e+00 | 0.00e+00 | 0.603 | 0.309 | Malignant cells | pre |
TPM4 | ENSG00000167460 | 0.877583 | 0.00e+00 | 0.00e+00 | 0.756 | 0.435 | Malignant cells | pre |
TIMP2 | ENSG00000035862 | 0.868426 | 0.00e+00 | 0.00e+00 | 0.366 | 0.075 | Malignant cells | pre |
ZFP36 | ENSG00000128016 | 0.865918 | 0.00e+00 | 0.00e+00 | 0.708 | 0.403 | Malignant cells | pre |
TRIB1 | ENSG00000173334 | 0.836696 | 0.00e+00 | 0.00e+00 | 0.654 | 0.364 | Malignant cells | pre |
WFDC2 | ENSG00000101443 | 0.816664 | 0.00e+00 | 0.00e+00 | 0.347 | 0.002 | Malignant cells | pre |
DUSP1 | ENSG00000120129 | 0.813411 | 0.00e+00 | 0.00e+00 | 0.893 | 0.693 | Malignant cells | pre |
MALAT1 | ENSG00000251562 | 0.812193 | 0.00e+00 | 0.00e+00 | 0.999 | 0.997 | Malignant cells | pre |
DUSP5 | ENSG00000138166 | 0.805991 | 0.00e+00 | 0.00e+00 | 0.655 | 0.434 | Malignant cells | pre |
DUSP2 | ENSG00000158050 | 0.803205 | 0.00e+00 | 0.00e+00 | 0.26 | 0.041 | Malignant cells | pre |
CCR10 | ENSG00000184451 | 0.793035 | 0.00e+00 | 0.00e+00 | 0.648 | 0.446 | Malignant cells | pre |
ANKRD28 | ENSG00000206560 | 0.789258 | 0.00e+00 | 0.00e+00 | 0.739 | 0.523 | Malignant cells | pre |
HIST2H2BE | NA | 0.788002 | 0.00e+00 | 0.00e+00 | 0.487 | 0.192 | Malignant cells | pre |
ABCB9 | ENSG00000150967 | 0.783408 | 0.00e+00 | 0.00e+00 | 0.478 | 0.195 | Malignant cells | pre |
OTUD1 | ENSG00000165312 | 0.772541 | 0.00e+00 | 0.00e+00 | 0.4 | 0.108 | Malignant cells | pre |
ACTB | ENSG00000075624 | 0.743545 | 0.00e+00 | 0.00e+00 | 0.992 | 0.889 | Malignant cells | pre |
PHLDA1 | ENSG00000139289 | 0.739905 | 0.00e+00 | 0.00e+00 | 0.369 | 0.154 | Malignant cells | pre |
HLA-C | ENSG00000206435 | 0.716857 | 0.00e+00 | 0.00e+00 | 0.994 | 1 | Malignant cells | pre |
DERL3 | ENSG00000274437 | 0.710295 | 0.00e+00 | 0.00e+00 | 0.937 | 0.858 | Malignant cells | pre |
KLF6 | ENSG00000067082 | 0.710195 | 0.00e+00 | 0.00e+00 | 0.776 | 0.676 | Malignant cells | pre |
HIST1H2AC | NA | 0.702212 | 0.00e+00 | 0.00e+00 | 0.556 | 0.27 | Malignant cells | pre |
CD63 | ENSG00000135404 | 0.683031 | 0.00e+00 | 0.00e+00 | 0.971 | 0.909 | Malignant cells | pre |
TMEM147 | ENSG00000105677 | 0.668988 | 0.00e+00 | 0.00e+00 | 0.841 | 0.789 | Malignant cells | pre |
HNRNPH1 | ENSG00000284254 | 0.668415 | 0.00e+00 | 0.00e+00 | 0.525 | 0.376 | Malignant cells | pre |
IER2 | ENSG00000160888 | 0.665256 | 0.00e+00 | 0.00e+00 | 0.587 | 0.536 | Malignant cells | pre |
ADM | ENSG00000148926 | 0.661268 | 0.00e+00 | 0.00e+00 | 0.406 | 0.222 | Malignant cells | pre |
FCRLA | ENSG00000132185 | 0.647188 | 0.00e+00 | 0.00e+00 | 0.339 | 0.099 | Malignant cells | pre |
PECAM1 | ENSG00000261371 | 0.640519 | 0.00e+00 | 0.00e+00 | 0.501 | 0.165 | Malignant cells | pre |
S100A4 | ENSG00000196154 | 0.637536 | 0.00e+00 | 0.00e+00 | 0.573 | 0.381 | Malignant cells | pre |
CLPTM1L | ENSG00000274811 | 0.630951 | 0.00e+00 | 0.00e+00 | 0.707 | 0.561 | Malignant cells | pre |
RAB30 | ENSG00000137502 | 0.621553 | 0.00e+00 | 0.00e+00 | 0.433 | 0.122 | Malignant cells | pre |
SPCS3 | ENSG00000129128 | 0.620621 | 0.00e+00 | 0.00e+00 | 0.938 | 0.891 | Malignant cells | pre |
CYBA | ENSG00000051523 | 0.617805 | 0.00e+00 | 0.00e+00 | 0.999 | 0.993 | Malignant cells | pre |
S100A10 | ENSG00000197747 | 0.616002 | 0.00e+00 | 0.00e+00 | 0.38 | 0.066 | Malignant cells | pre |
LDHB | ENSG00000111716 | 0.615967 | 0.00e+00 | 0.00e+00 | 0.834 | 0.68 | Malignant cells | pre |
SELENOM | ENSG00000198832 | 0.614126 | 0.00e+00 | 0.00e+00 | 0.758 | 0.49 | Malignant cells | pre |
UBC | ENSG00000150991 | 0.589643 | 0.00e+00 | 0.00e+00 | 0.999 | 0.997 | Malignant cells | pre |
VIM | ENSG00000026025 | 0.579001 | 0.00e+00 | 0.00e+00 | 0.97 | 0.792 | Malignant cells | pre |
CHCHD10 | ENSG00000273607 | 0.576026 | 0.00e+00 | 0.00e+00 | 0.759 | 0.555 | Malignant cells | pre |
TECR | ENSG00000099797 | 0.575192 | 0.00e+00 | 0.00e+00 | 0.798 | 0.625 | Malignant cells | pre |
FTL | ENSG00000087086 | 0.571497 | 0.00e+00 | 0.00e+00 | 1 | 0.999 | Malignant cells | pre |
PPP1R15A | ENSG00000087074 | 0.560937 | 0.00e+00 | 0.00e+00 | 0.687 | 0.505 | Malignant cells | pre |
NENF | ENSG00000117691 | 0.559414 | 0.00e+00 | 0.00e+00 | 0.695 | 0.629 | Malignant cells | pre |
TRPM4 | ENSG00000130529 | 0.556293 | 0.00e+00 | 0.00e+00 | 0.315 | 0.003 | Malignant cells | pre |
AC020916.1 | NA | 0.552368 | 0.00e+00 | 0.00e+00 | 0.302 | 0.083 | Malignant cells | pre |
PELI1 | ENSG00000197329 | 0.552198 | 0.00e+00 | 0.00e+00 | 0.441 | 0.172 | Malignant cells | pre |
ITM2C | ENSG00000135916 | 0.549576 | 0.00e+00 | 0.00e+00 | 0.94 | 0.938 | Malignant cells | pre |
HLA-DOB | ENSG00000243612 | 0.547409 | 0.00e+00 | 0.00e+00 | 0.512 | 0.262 | Malignant cells | pre |
UBALD2 | ENSG00000185262 | 0.544062 | 0.00e+00 | 0.00e+00 | 0.558 | 0.325 | Malignant cells | pre |
RASGRP3 | ENSG00000152689 | 0.534491 | 0.00e+00 | 0.00e+00 | 0.545 | 0.282 | Malignant cells | pre |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
![]() |
Gene symbol | Gene id | avg_log2FC | p_val | p_val_adj | pct.1 | pct.2 | Cell type | Timepoint |
AIF1 | ENSG00000235588 | 1.07763 | 5.52e-07 | 1.19e-02 | 0.757 | 0.296 | Progenitors | post |
RPL39 | ENSG00000198918 | 0.827345 | 1.98e-08 | 4.27e-04 | 1 | 1 | Progenitors | post |
ZNF394 | ENSG00000160908 | -0.311907 | 1.68e-06 | 3.63e-02 | 0.044 | 0.259 | Progenitors | post |
DUS1L | ENSG00000169718 | -0.341472 | 2.69e-07 | 5.81e-03 | 0.05 | 0.296 | Progenitors | post |
HSD17B8 | ENSG00000228357 | -0.347 | 1.35e-07 | 2.91e-03 | 0.048 | 0.296 | Progenitors | post |
HMBS | ENSG00000256269 | -0.363495 | 1.10e-06 | 2.37e-02 | 0.115 | 0.444 | Progenitors | post |
ALAD | ENSG00000148218 | -0.370009 | 2.05e-09 | 4.42e-05 | 0.058 | 0.37 | Progenitors | post |
STXBP6 | ENSG00000168952 | -0.370657 | 8.28e-07 | 1.79e-02 | 0.066 | 0.333 | Progenitors | post |
SMIM10 | ENSG00000184785 | -0.389446 | 3.65e-08 | 7.89e-04 | 0.068 | 0.37 | Progenitors | post |
HES6 | ENSG00000144485 | -0.440493 | 8.19e-10 | 1.77e-05 | 0.056 | 0.37 | Progenitors | post |
PSMC4 | ENSG00000281221 | -0.454981 | 1.83e-06 | 3.96e-02 | 0.125 | 0.444 | Progenitors | post |
SMIM1 | ENSG00000235169 | -0.472998 | 1.62e-06 | 3.49e-02 | 0.105 | 0.407 | Progenitors | post |
UBAC1 | ENSG00000130560 | -0.48079 | 4.31e-07 | 9.30e-03 | 0.115 | 0.444 | Progenitors | post |
APOE | ENSG00000130203 | -0.481737 | 3.64e-08 | 7.87e-04 | 0.095 | 0.444 | Progenitors | post |
MT-ND1 | ENSG00000198888 | -0.658373 | 7.90e-07 | 1.71e-02 | 0.968 | 1 | Progenitors | post |
BLVRB | ENSG00000090013 | -0.851717 | 8.44e-10 | 1.82e-05 | 0.282 | 0.852 | Progenitors | post |
APOC1 | ENSG00000130208 | -1.11993 | 1.24e-06 | 2.68e-02 | 0.199 | 0.593 | Progenitors | post |
HBB | ENSG00000244734 | 1.18003 | 3.93e-41 | 8.49e-37 | 0.581 | 0.284 | NK cells | post |
S100B | ENSG00000160307 | 1.12001 | 7.89e-34 | 1.70e-29 | 0.338 | 0.07 | NK cells | post |
GZMB | ENSG00000100453 | 0.918432 | 5.08e-29 | 1.10e-24 | 0.871 | 0.849 | NK cells | post |
RPS26 | ENSG00000197728 | 0.890028 | 0.00e+00 | 0.00e+00 | 0.995 | 0.955 | NK cells | post |
IFI6 | ENSG00000126709 | 0.589674 | 2.89e-11 | 6.25e-07 | 0.368 | 0.228 | NK cells | post |
HBA2 | ENSG00000188536 | 0.574351 | 6.80e-23 | 1.47e-18 | 0.314 | 0.094 | NK cells | post |
RPS4Y1 | ENSG00000129824 | 0.567874 | 2.54e-32 | 5.49e-28 | 0.521 | 0.183 | NK cells | post |
FCER1G | ENSG00000158869 | 0.511785 | 8.12e-20 | 1.75e-15 | 0.697 | 0.492 | NK cells | post |
BST2 | ENSG00000130303 | 0.508996 | 1.36e-20 | 2.94e-16 | 0.516 | 0.284 | NK cells | post |
XCL1 | ENSG00000143184 | 0.504597 | 2.18e-20 | 4.70e-16 | 0.282 | 0.087 | NK cells | post |
SELL | ENSG00000188404 | 0.49836 | 2.59e-16 | 5.59e-12 | 0.438 | 0.243 | NK cells | post |
S100A8 | ENSG00000143546 | 0.488599 | 3.86e-15 | 8.33e-11 | 0.67 | 0.488 | NK cells | post |
XCL2 | ENSG00000143185 | 0.487371 | 1.92e-08 | 4.14e-04 | 0.395 | 0.279 | NK cells | post |
KLF2 | ENSG00000127528 | 0.485911 | 8.48e-15 | 1.83e-10 | 0.469 | 0.29 | NK cells | post |
KLRC1 | ENSG00000134545 | 0.479539 | 5.02e-16 | 1.08e-11 | 0.452 | 0.252 | NK cells | post |
S100A11 | ENSG00000163191 | 0.471548 | 2.26e-23 | 4.87e-19 | 0.676 | 0.411 | NK cells | post |
CD7 | ENSG00000173762 | 0.460036 | 9.59e-16 | 2.07e-11 | 0.743 | 0.589 | NK cells | post |
ISG15 | ENSG00000187608 | 0.439379 | 1.91e-07 | 4.13e-03 | 0.441 | 0.33 | NK cells | post |
LY6E | ENSG00000278032 | 0.431186 | 4.64e-12 | 1.00e-07 | 0.755 | 0.653 | NK cells | post |
CMC1 | ENSG00000187118 | 0.410288 | 1.48e-10 | 3.20e-06 | 0.707 | 0.535 | NK cells | post |
H1FX | NA | 0.367523 | 1.55e-07 | 3.35e-03 | 0.365 | 0.241 | NK cells | post |
MT-ND3 | ENSG00000198840 | 0.353543 | 1.59e-18 | 3.43e-14 | 0.996 | 0.987 | NK cells | post |
LTB | ENSG00000223448 | 0.34478 | 5.80e-08 | 1.25e-03 | 0.316 | 0.194 | NK cells | post |
S100A9 | ENSG00000163220 | 0.341221 | 7.68e-09 | 1.66e-04 | 0.693 | 0.574 | NK cells | post |
PRF1 | ENSG00000180644 | 0.340554 | 3.57e-08 | 7.72e-04 | 0.843 | 0.789 | NK cells | post |
CLIC3 | ENSG00000169583 | 0.327308 | 2.35e-07 | 5.07e-03 | 0.479 | 0.356 | NK cells | post |
RPLP1 | ENSG00000137818 | 0.324989 | 2.67e-24 | 5.76e-20 | 1 | 1 | NK cells | post |
IGFBP7 | ENSG00000163453 | 0.323051 | 3.33e-10 | 7.19e-06 | 0.277 | 0.143 | NK cells | post |
GZMK | ENSG00000113088 | 0.321295 | 5.07e-07 | 1.09e-02 | 0.371 | 0.252 | NK cells | post |
IL2RB | ENSG00000100385 | 0.321022 | 4.58e-10 | 9.89e-06 | 0.508 | 0.365 | NK cells | post |
ALOX5AP | ENSG00000132965 | 0.316729 | 2.94e-07 | 6.35e-03 | 0.385 | 0.264 | NK cells | post |
DDIT4 | ENSG00000168209 | 0.312745 | 2.29e-08 | 4.95e-04 | 0.407 | 0.269 | NK cells | post |
HBA1 | ENSG00000206172 | 0.305774 | 6.59e-13 | 1.42e-08 | 0.329 | 0.162 | NK cells | post |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Top |
Mechanism analysis of drug resistance-related DEGs for each cell type in the pre-treatment samples |
![]() |
Enrichment results for 5 known drug-resistant mechanisms in malignant cells |
![]() |
Mechnism | Pval | FDR | Signature | Geneset | Overlap | Background | Cell type | Enriched Genes |
Unusual Activation of Pro-survival Pathway | 1.70e-12 | 8.50e-12 | 486 | 781 | 50 | 23467 | Malignant cells | ANXA2,AREG,BCL2L11,FBXW7,GSTP1,HMGB1,IFI27,ISG15,JUN,MCL1,RHOA,S100A4,STMN1,TP53INP1,VOPP1,YWHAZ,SLC25A5,HSPA5,BMI1,CCND1,CCNG1,HSPD1,CXCR4,DUSP1,DUSP2,EGR1,HSP90B1,FTL,GAPDH,HMGB2,HSPA8,NFKBIA,MTDH,MDM4,NSD2,NUCKS1,PABPC1,RAC1,HNRNPA1,S100A11,SIAH2,TPT1,UCP2,YBX1,CALR,FGFR3,NPM1,MDK,RCN1,PMVK |
Epigenetic Alteration of DNA, RNA or Protein | 1.50e-01 | 3.80e-01 | 486 | 455 | 13 | 23467 | Malignant cells | BCL2L11,FBXW7,LMNA,PMAIP1,BMI1,CXCR4,GAPDH,TIMP1,CYTOR,MALAT1,PPP1R15A,MT-CO2,MX1 |
Drug Inactivation by Structure Modification | 4.30e-01 | 5.60e-01 | 486 | 27 | 1 | 23467 | Malignant cells | GSTP1 |
Irregularity in Drug Uptake and Drug Efflux | 5.40e-01 | 5.60e-01 | 486 | 37 | 1 | 23467 | Malignant cells | ABCB9 |
Aberration of the Drug's Therapeutic Target | 5.60e-01 | 5.60e-01 | 486 | 90 | 2 | 23467 | Malignant cells | FGFR3,NPM1 |
Enrichment results for 1 known drug resistance mechanisms in TME cells |
![]() |
Mechnism | Pval | FDR | Signature | Geneset | Overlap | Background | Cell type | Enriched Genes |
Regulation by the Disease Microenvironment | 6.90e-02 | 6.90e-02 | 119 | 186 | 3 | 23467 | B cells | MYC,CXCR4,VIM |
Regulation by the Disease Microenvironment | 6.40e-02 | 6.40e-02 | 52 | 186 | 2 | 23467 | CD4+ T cells | SOCS3,VIM |
Regulation by the Disease Microenvironment | 2.00e-01 | 2.00e-01 | 103 | 186 | 2 | 23467 | CD8+ T cells | VIM,MALAT1 |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 59 | 186 | 0 | 23467 | cDCs | NA |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 40 | 186 | 0 | 23467 | Erythrocytes | NA |
Regulation by the Disease Microenvironment | 1.40e-01 | 1.40e-01 | 82 | 186 | 2 | 23467 | Mono_Macro | IL1B,VIM |
Regulation by the Disease Microenvironment | 2.50e-01 | 2.50e-01 | 122 | 186 | 2 | 23467 | NK cells | CXCR4,VIM |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 1 | 186 | 0 | 23467 | pDCs | NA |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 13 | 186 | 0 | 23467 | Progenitors | NA |
![]() |
Up-regulated Hallmark | Up-regulated KEGG | Up-regulated GO BP |
![]() | ![]() | ![]() |
![]() |
Down-regulated Hallmark | Down-regulated KEGG | Down-regulated GO BP |
![]() | ![]() | ![]() |
Top |
Mechanism analysis of drug resistance-related DEGs for each cell type in the post-treatment samples |
![]() |
Enrichment results for 5 known drug resistance mechanisms in malignant cells |
![]() |
Mechnism | Pval | FDR | Signature | Geneset | Overlap | Background | Cell type | Enriched Genes |
Unusual Activation of Pro-survival Pathway | 2.20e-07 | 1.10e-06 | 511 | 781 | 41 | 23467 | Malignant cells | ANXA2,CCND2,CDKN1A,CFLAR,FBXW7,GSTP1,IDH2,IFI27,ISG15,MAP1LC3B,MYC,RHOA,RPS6,S100A4,HSPA5,CCND1,HSPD1,CXCR4,DKK1,HSP90B1,GAPDH,HAX1,HMGB2,HSPA8,NFKBIA,LDHA,NSD2,NUCKS1,PDCD4,POMP,SRSF2,UCP2,ENO1,CALR,FGFR3,INSIG1,MDK,RCN1,PMVK,QPRT,APP |
Drug Inactivation by Structure Modification | 4.50e-01 | 6.60e-01 | 511 | 27 | 1 | 23467 | Malignant cells | GSTP1 |
Irregularity in Drug Uptake and Drug Efflux | 5.60e-01 | 6.60e-01 | 511 | 37 | 1 | 23467 | Malignant cells | SLC3A2 |
Aberration of the Drug's Therapeutic Target | 5.90e-01 | 6.60e-01 | 511 | 90 | 2 | 23467 | Malignant cells | IDH2,FGFR3 |
Epigenetic Alteration of DNA, RNA or Protein | 6.60e-01 | 6.60e-01 | 511 | 455 | 9 | 23467 | Malignant cells | FBXW7,IDH2,PMAIP1,CXCR4,GAPDH,PDCD4,CYTOR,MALAT1,PPP1R15A |
Enrichment results for 1 known drug resistance mechanisms in TME cells |
![]() |
Mechnism | Pval | FDR | Signature | Geneset | Overlap | Background | Cell type | Enriched Genes |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 31 | 186 | 0 | 23467 | B cells | NA |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 81 | 186 | 0 | 23467 | CD4+ T cells | NA |
Regulation by the Disease Microenvironment | 4.90e-01 | 4.90e-01 | 85 | 186 | 1 | 23467 | CD8+ T cells | CXCR4 |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 8 | 186 | 0 | 23467 | cDCs | NA |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 29 | 186 | 0 | 23467 | Erythrocytes | NA |
Regulation by the Disease Microenvironment | 4.80e-01 | 4.80e-01 | 82 | 186 | 1 | 23467 | Mono_Macro | IL1B |
Regulation by the Disease Microenvironment | 5.10e-01 | 5.10e-01 | 89 | 186 | 1 | 23467 | NK cells | CXCR4 |
Regulation by the Disease Microenvironment | 1.00e+00 | 1.00e+00 | 17 | 186 | 0 | 23467 | Progenitors | NA |
![]() |
Up-regulated Hallmark | Up-regulated KEGG | Up-regulated GO BP |
![]() | ![]() | ![]() |
![]() |
Down-regulated Hallmark | Down-regulated KEGG | Down-regulated GO BP |
![]() | ![]() | ![]() |
Top |
Mechanism analysis of drug resistance-related DEGs for each cell type in one patient or cell lines |
![]() |
![]() |
![]() |
Top |
MicroRNAs (miRNAs) regulating drug resistance-related DEGs for malignant cells |
![]() |
Regulating up-regulated DEGs in resistant group | Regulating down-regulated DEGs in resistant group |
![]() | ![]() |
![]() |
Regulating up-regulated DEGs in resistant group | Regulating down-regulated DEGs in resistant group |
![]() | ![]() |
![]() |
Top |
Motifs and transcription factors (TFs) regulating drug resistance-related DEGs for each cell type |
![]() |
Motifs and TFs regulating up-regulated DEGs in resistant group of the pre-treatment samples |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 |
Motifs and TFs regulating down-regulated DEGs in resistant group of the pre-treatment samples |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 |
![]() |
Motifs and TFs regulating up-regulated DEGs in resistant group of the post-treatment samples |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 |
Motifs and TFs regulating down-regulated DEGs in resistant group of the post-treatment samples |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 |
![]() |
Top |
Differentially expressed genes act as transcription factors |
![]() |
TF | motif | Expression | Cell type | Timepoint |
FOS | tfdimers__MD00090 | down | CD4+ T cells | post |
SCAND1 | metacluster_130.3 | down | CD8+ T cells | post |
JUN | metacluster_111.4 | down | CD8+ T cells | post |
JUND | metacluster_111.4 | down | CD8+ T cells | post |
FOS | metacluster_111.4 | down | CD8+ T cells | post |
FOS | metacluster_137.2 | down | CD8+ T cells | post |
JUN | metacluster_137.2 | down | CD8+ T cells | post |
JUND | metacluster_137.2 | down | CD8+ T cells | post |
JUN | metacluster_180.3 | down | CD8+ T cells | post |
JUND | metacluster_180.3 | down | CD8+ T cells | post |
Page: 1 |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |